Neuromeningeal prophylaxis for diffuse large B-cell lymphoma.

##plugins.themes.academic_pro.article.sidebar##

Published Apr 5, 2018
Download
pdf
Vol. 95 No. 10 (2017): Issue Oct 2017

##plugins.themes.academic_pro.article.main##

Karima Kacem
Sami Zriba

Abstract

The neuromeningeal relapse of diffuse large B-cell lymphomais a rare complication with a poor prognosis due to early mortality. Some risk factors are associated with an increased risk of neuromeningeal relapse: elevated LDH, more than one extranodal site and certain anatomical sites. Place and methods of neuromeningeal prophylaxis are points that remain to be defined. In this review we underwent an extensive search of literature and we reviewed the incidence of CNS relapse in diffuse large B-cell lymphomaand we outlined different strategies of administering CNS prophylaxis and we discussed their advantages and drawbacks.

Keywords:

##plugins.themes.academic_pro.article.details##

References

  1. Mead GM, Kennedy P, SmithJL et al. Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A review of 36 cases. Q J Med 1986; 60:699-714.
  2. Doolittle ND, Abrey LE, ShenkierTN et al. Brain parenchyma involvement as isolated central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma: An international Primary CNS Lymphoma Collaborative Group report. Blood 2008; 111:1085-93.
  3. Van Horn A. Lymphomatous Meningitis: Early Diagnosis and treatment. ClinJOncolNurs 2009;13:90-4.
  4. Zhang J, Chen B, XuX. Impact of Rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis. Leuk Lymphoma 2014; 55:509-14.
  5. Boehme V, Zeynalova S, Kloess M et al.Incidence and risk factors of central nervous system recurrence in aggressive Lymphoma- a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18:149-57.
  6. Tilly H, Lepage E, Coiffier Bet al.Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102:4284-9.
  7. Feugier P, Virion JM, TillyH et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of Rituximab. Ann Oncol 2004; 15:129-33.
  8. Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 2000; 11:685-90.
  9. Arkenau HT, Chong G, Cunningham D et al.The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007; 18:541-5.
  10. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI.Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: A 20 year follow-up analysis of SWOG 8516-The Southwest Oncology Group. JClin Oncol 2009; 27:114-9.
  11. Abhimanyu G, Harold Kunal E, Gunjan G, Mahender Y, Rin K, Tahir L.Secondary CNS relapse in DLBCL in the Rituximab Era- An analysis of Prospective studies. Blood 2014, 124:1644.
  12. Boehme V, Schmitz N, Zeynalova S, Loeffler M, PfreundschuhM.CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHO-P14) with or without rituximab: An analysis of patients treated in the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113:3896-902.
  13. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ.Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21:1046-52.
  14. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009; 89:577-83.
  15. Cai QQ, Hu LY, GengQR et al.New risk factors and new tendency for centralnervous system relapse in patients with diffuse large B- cell lymphoma: a retrospective study. Chin J Cancer 2016; 35:87.
  16. Mitrovic Z, Bast M, BiermanPJ et al.The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Br J Haematol 2012; 157:401-3.
  17. Zucca E, Roggero E, Bertoni F et al.Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol, 1999; 10:1023-33.
  18. Liang R, Chin E, LokeSL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 1990; 8:141-5.
  19. Gholam D, Bibeau F, El Weshi A, Bosq J, Ribrag V. Primary breast lymphoma. Leuk Lymphoma 2003; 44:1173-8.
  20. McMillan A, ARDESHNA KM, CWYNARSKI K, LYTTELTON M, MckayP, MONTOLO S. Guideline of the prevention of secondary central nervous system lymphoma. British committee for standards in haematology.Br J Haematol 2013; 163:168-81.
  21. Van Besien K, Ha CS, Murphy Set al. Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblasticlymphoma. Blood 1998; 91:1178-84.
  22. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol.2002; 13:1099-107.
  23. Chihara D, Oki Y, Matsuo K et al.Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model.Leuk Lymphoma 2011; 52:2270-5.
  24. Nitta H, Termi Y, Yokoyama M et al.Absolute Peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B- cell lymphoma. Haematologica 2014; 100: 87- 90.
  25. Aukema SM, Siebert R, SchuuringE et al.Double- hit B cell lymphomas. Blood 2011; 117:2319- 31.
  26. Kridel R, Dictrich PY. Prevention of CNS relapse in diffuse large B- cell lymphoma. Lancet Oncol 2011; 12: 1258- 66.
  27. Schmitz N, Zeynalova S, GlassBet al.CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.Ann Oncol 2012;23: 1267-73.
  28. Safar V. Prophylaxie neuro-méningée dans le lymphoma B diffuse à grandes cellules: quand et comment? Horizons Hémato 2015 ;5(3) :175-6
  29. Fletcher CD, KahlBS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk lymphoma 2014; 55 (10):2228-40.
  30. Tomita N, Kodama F, Kanamori H, Motomura S, IshigatsuboY. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 2002; 95:576-80.
  31. Vitolo U, Chiapella A, Ferreri AJ et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP,CNS prophylaxis and controlateral testis irradiation: final results of an international phase II trial. JClin Oncol 2011, 29:2766-72.
  32. Tai WM, Chung J, TangPL et al.Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre and post-rituximab. Ann Hematol.2011; 90: 809-18.
  33. Kumar A, Vanderplast A, LacasceAS et al.Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Finding from a large national database. Cancer 2012; 118:2944-51.
  34. Spina M, Chimienti E, MartellotaF et al. Phase 2 study of intrathecal, long- acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus- related non Hodgkin lymphoma. Cancer 2010; 116: 1495- 501.
  35. Ferreri A J, Reni M, Pasini F et al.A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58:1513-20.
  36. Ferreri Aj, Guerra E, RegazziM et al. Area under the curve of Methotrexate and creatinine clearance areoutcome-determining factors in primary CNS lymphomas. Br J Cancer 2004; 90:353-8.
  37. Joerger M, FerreriAj, KrähenbühlS et al. Dosing algorithm to target a defined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J ClinPharmacol 2012; 73:240-7.
  38. Brugieres L, LeDeley Mc, RosolenA et al.Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. JCO 2009; 27:897- 903.
  39. Abramson JS, Hellmann M, Barnes JA et al.Intra-venous methotrexate as central nervous System (CNS) prophylaxis is associated with a low risk patients with diffuse large B- cell lymphoma. Cancer 2010;116: 4283- 90.
  40. Ferreri ASJM, Bruno-Ventre M, DonadoniG et al.Risk- tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B- cell lymphoma treated in the Rituximab era. Br J Haematol 2015; 168:654- 62.
  41. Zahid MF, Khan N, HashmiSK et al.Central nervous system prophylaxis in diffuse large B- cell lymphoma. Eur JHaematol 2016; 97: 108- 120.